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Chemokine-glycosaminoglycan (GAG) interactions have been shown to be essential for in vivo
chemokine signaling, which functions in such diverse processes as inflammation, develop-
ment, and cancer metastasis. Despite the importance of these interactions, the saccharide
sequence dependency of chemokine-GAG interactions is poorly understood. In a recent study,
FT-ICR mass spectrometry was used to show that the chemokine CCL2 (monocyte chemoat-
tractant protein 1) binds only to the 11- and 12-sulfated components of a heparin octasaccha-
ride library. Although the exact structure of the fully sulfated, 12-sulfated octasaccharide is
known, the 11-sulfated species could have a number of sulfated disaccharide sequences. In the
current study, the composition of the 11-sulfated heparin octasaccharides, as well as the
composition of CCL2 affinity purified 11-sulfated heparin octasaccharides, were examined by
tandemMS. Of the three possible singly desulfated disaccharides, one species, III-S, is enriched
by CCL2 affinity purification, indicating that the 11-sulfated heparin octasaccharides contain-
ing this disaccharide are preferentially bound to CCL2. These data suggest that 2-O and N
sulfation of heparin may be of greater importance to CCL2-heparin binding than 6-O
sulfation. (J Am Soc Mass Spectrom 2006, 17, 1114–1119) © 2006 American Society for Mass
SpectrometryChemokine mediated signaling depends not onlyon the ability of a chemokine to complex withand activate a receptor, but also on the forma-
tion of a chemokine concentration gradient that directs
chemotaxis. Chemokines diffuse away from the site of
secretion until they bind cell-surface glycosaminogly-
cans (GAGs) resulting in the formation of a chemotactic
gradient that can be followed by certain motile cell
types [1, 2]. While mutant chemokines that are unable
to bind GAGs can still bind receptor and signal in vitro,
they are unable to recruit immune cells in vivo [3, 4].
Despite the importance of GAG-chemokine binding, the
role of the specific sequence of the GAG component is
poorly understood.
The principle GAG ligand for inflammatory chemo-
kines is cell-surface heparan sulfate [5]. Both heparan
sulfate and the more highly sulfated heparin contain,
upon enzymatic digestion of the polymers, 12 common
disaccharide subunits, not including changes to epimer-
ization or the 3-O sulfate isomers [6]. This results in a
high degree of sequence complexity for even fairly
short chains. In spite of this heterogeneity, GAG bind-
ing sequence specificity has been observed to various
Published online June 2, 2006
Address reprint requests to Dr. J. A. Leary, Genome Center, Department of
Chemistry, Room 1300, University of California, 1 Shields Avenue, Davis,
CA 95616, USA. E-mail: jaleary@ucdavis.edu
© 2006 American Society for Mass Spectrometry. Published by Elsevie
1044-0305/06/$32.00
doi:10.1016/j.jasms.2006.04.025extents in binding to proteins such as the members of
the FGF family [7–9]. The rare 3-O sulfation further
increases the possible complexity of heparinoids, and
has been shown to be essential in heparin binding to
antithrombin III [10, 11] and in herpes simplex virus 1
infection [12].
As most inflammatory chemokines are positively
charged and heparin and heparan sulfate are negatively
charged, ionic and electrostatic interactions are clearly
important in chemokine-GAG binding, however it is
unclear what role GAG sulfate positioning plays in
possible selectivity of chemokine binding sites. In a
recent study, it was shown that the five chemokine
ligands of chemokine receptor 2 (CCR2) bind to only
the highly sulfated components of a heparin octasac-
charide library [13]. One of these chemokines, CCL2
(CC chemokine ligand 2), was shown to bind only to
heparin octasaccharide that is either fully sulfated (12-
sulfate) or singly unsulfated (11-sulfate). This finding
was surprising in that heparan sulfate, the principle
GAG ligand for CCL2, is not highly sulfated, though
local patches of high sulfation (S-domains) exist con-
nected by less sulfated regions in the chain [14]. If such
highly sulfated stretches of GAG are the binding sites
for CCL2, the possible sequence complexity of heparan
sulfate in these epitopes decreases dramatically. Studies
of the binding of heparan sulfate to the chemokines
interleukin-8 (CXCL8), platelet factor 4 (CXCL4), and
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tified chemokine binding sites consisting of fairly large
sequences of 14 –24 saccharides [15–17]. These binding
sites appear to consist of two S-domains connected by a
less sulfated region.
The heparin octasaccharide which binds to CCL2 is
structurally similar to heparan sulfate S-domain, and by
examining the determinates of CCL2 binding to highly
sulfated sequences of heparin, information on the rela-
tive importance of positional sulfation in CCL2 binding
to highly sulfated heparan sulfate may be ascertained.
The octasaccharide in our library was generated by
heparinase I digestion, which cleaves heparin only after
N-sulfated glucosamine and before 2-O sulfated idur-
onate or 2-O sulfated glucoronate, leaving N- and 2-O
sulfated terminal sugars [18, 19]. Given this constraint,
the 11-sulfated octasaccharide can be unsulfated at only
ten possible sites, resulting in only ten possible disac-
charide sulfation sequences. To investigate the possibil-
ity of sequence selectivity by CCL2 in heparin binding,
we purified the 11-sulfated octasaccharides, screened
these octasaccharides for CCL2 binding, and deter-
mined the disaccharide composition of both the initial
11-sulfated octasaccharide library and of the CCL2
affinity enriched 11-sulfated octasaccharide using an
ESI tandem mass spectrometry.
Sensitivity and speed make mass spectrometry an
attractive approach for analysis of sulfated glycosami-
noglycans. One issue of concern is the liability of the
sulfate groups on these molecules, however solvent
conditions can be manipulated to minimize this loss [20,
21]. Complete enzymatic digestion to disaccharide sub-
units for compositional analysis overcomes the problem
of sulfate loss, but has the disadvantage that any
information about uronic acid epimerization or se-
quence is lost [6, 22]. Methods using partial digestion,
isotopic labeling, and LC-MS have been developed
[23–26], and these studies have helped to propel for-
ward the field of GAG analysis. It is import to note,
however, that these methods are still somewhat sensi-
tive to glycosaminoglycan length and heterogeneity.
Materials and Methods
Reagents and Instrumentation
Heparin octassacharide library was purchased from
Dextra (Reading, UK). CarboPac PA1 ion-exchange
column was purchased from Dionex (Sunnyvale, CA).
High-pressure liquid chromatography (HPLC) grade
solvents were purchased from Fisher (Santa Clara, CA).
SAX HPLC was purchased from Waters (Milford, MA).
Heparin desalting was performed using 1 kDa Dispo-
Biodialyzers (The Nest Group, Southborough, MA).
Oasis HLB C18 column was purchased from Waters
(Milford, MA). Heparinase I, II, and III were purchased
from Seikagaku (East Falmouth, MA). Disaccharide
standards were purchased from Sigma-Aldich (St.
Louis, MO). Heparin disaccharide stock solutions wereprepared at concentrations of 2 mM on the basis of their
absorbance at 232 nm in 0.03 M HCl 232  5500 M
1
cm1) [27].
High-resolution mass spectra were acquired on a
Bruker APEX II 7-tesla FT-ICR (Billerica, MA) mass
spectrometer that was equipped with an Apollo
(Bruker) electrospray ionization (ESI) source. Samples
in a solvent of 1:1 MeOH/H2O with 20 mM NH4OH
were infused into the mass spectrometer at 1 L/min
using a syringe pump (Harvard Apparatus, Holliston,
MA). Nitrogen at 50 psi was used as the nebulizing gas,
while capillary exit voltage was adjusted to 40 V for ion
desolvation. Ions were externally accumulated in a
radio frequency-only hexapole for 0.5 s. Ions were
trapped using gated trapping and detected using neg-
ative polarity. All the data were acquired and processed
using Xmass version 6.0.0 (Bruker).
Mass spectra for compositional analysis were ob-
tained by using an ESI source on an LTQ MS (Ther-
moFinnigan, San Jose, CA). Disaccharide standards
were sprayed at a concentration of 20 pmol/L for each
disaccharide (20 pmol/L total disaccharide concentra-
tion for experimental samples) in a 1:1 MeOH/H2O
solution containing 10 mM NH4OH, 2 mM NH4OAc,
0.2 mM Ca(OAc)2, and 5 pmol/L internal standard
I-P. Samples were introduced by flow injection at 20
L/min in 1:1 MeOH/H2O using a syringe pump
(Harvard Apparatus). Spectra were obtained in nega-
tive ion mode by using a spray voltage of 3.8 kV and a
capillary temperature of 230°C for all experiments. For
MS2 experiments, a 4 Da isolation width was used for
precursor ion selection, and the ion was activated at
21% normalized collision energy for 100 ms, and the qz
value was maintained at 0.250. Each mass spectrum
obtained contains an average of 10 scans. Xcalibur,
version 1.4 (ThermoFinnigan), was used for data acqui-
sition.
Preparation of 11-Sulfated Heparin Octasaccharide
Heparin octasaccharide with 11 sulfates was isolated
from the heparin octasaccharide mixture by using
strong anion-exchange HPLC. Approximately 400 g of
an octasaccharide library was injected onto a CarboPac
PA1 column and SAX HPLC was performed at a flow
rate of 1 mL/min using Solvent A (H2O, pH 3.5) and
Solvent B (3 M NaCl, pH 3.5). A typical gradient
consisted of: (1) 1–11 min, 0% B, (2) 11–110 min, 0-100%
B, and (3) 111–120 min, 0% B. Chromatograms were
recorded by monitoring the UV absorbance at 232 nm.
Fractions corresponding to 11-sulfated octasaccharide
were collected, lyophilized and desalted.
Preparation of CCL2
CCL2 was expressed, purified, and processed as previ-
ously described [28]. Briefly, CCL2 was expressed using
a codon-optimized construct in TAP302 cells. Soluble
CCL2 was purified by ion-exchange chromatography
um a
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chromatography (RP-HPLC). The N-terminal methio-
nine was removed by aminopeptidase, leaving authen-
tic human CCL2 that was then subject to re-purification
by RP-HPLC.
CCL2 Affinity Enrichment of 11-Sulfated
Octasaccharide
Octasaccharide was enriched by incubating 40 M
CCL2 with 200 M 11-sulfate octasaccharide in 100 L
of 100 mMNH4OAc solution (pH 6.8). The solution was
applied to an Oasis solid-phase extraction (SPE) car-
tridge (Waters, Milford, MA) that had been previously
conditioned using 1 mL of methanol and then 1 mL of
H2O. The solid-phase SPE cartridge was flushed three
times, each using 1 mL 200 mM NH4OAc solution (pH
6.8) and then eluted by 1 mL 760 mMNH4OAc (pH 6.8).
The three washing fractions and the final elution faction
were collected and desalted by dialyzing against water
using a dialyzer with a molecular weight cutoff
(MWCO) of 1 kDa.
Compositional Analysis of Affinity Purified
Heparin Octasaccharide
Enzymatic digestion of heparin octasaccharide to con-
stituent disaccharides was carried out with 5 g hepa-
rin in 20 L of 20 mM ammonium acetate buffer, pH
7.5, 2 mM calcium acetate, and 0.001 unit each of
heparinase I, heparinase II, and heparinase III, which
was incubated at 37°C for 16 h. The reaction was
100
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*
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Figure 1. Preparation of heparin octasaccharide
HPLC separation of heparin octasaccharide libra
desalted. (b) ESI-FTICR mass spectra of the fract
ride (Octa/11SO3). Asterisks represents the sodiquenched yielding a final solution containing 20pmol/L heparin disaccharide, 1:1 MeOH/H2O, 5
pmol/L internal standard I-P, and 10 mM ammonium
hydroxide. Samples were then analyzed using a combi-
nation of ESI-MS and MS-MS on an LTQ mass spec-
trometer. An MS1 step is used to quantify the noniso-
meric disaccharide and the total combined
concentration of isomeric disaccharides by comparing
peak intensities with the peak intensity of the internal
standard, I-P. The second MS2 step is then used to
determine the relative concentrations of each of the m/z
247.7 isomers by observing ratios of diagnostic ions that
are formed by collision-induced dissociation of the
parent ions. Both experimental and control samples
were analyzed in triplicate: i.e., each sample work-up
and analysis was preformed three times on three differ-
ent days. Data were processed using QualBrowser
(ThermoFinnigan) and Excel (Microsoft). This method
has been used previously to quantify complicated mix-
tures of 12 heparin disaccharides, and gives results
comparable to HPLC analysis [6, 29].
Results and Discussion
To obtain the 11-sulfated heparin octasaccharide, it was
necessary to fractionate the heparin octasaccharide li-
brary on the basis of charge. The octasaccharide library,
which contained between 8 and 12 sulfates per mole-
cule, was applied to a strong anion exchange column
(CarboPac PA1) and eluted using a linear NaCl gradi-
ent, yielding well resolved peaks corresponding to the
extent of sulfation (Figure 1a). The penultimate peak to
elute was collected, desalted extensively, and analyzed
450 m/z
* *
400
[Octa/11SO3]5-
5.00 80.00 85.00 90.00 Time95.00 100.00 105.00
ified with 11 sulfates. (a) Chromatogram of SAX
action indicated by the arrow was collected and
orresponding to 11-sulfated heparin octasaccha-
dducts.6-
70.00 7
mod
ry. Fr
ion cby FT-ICR mass spectrometry, which yielded an ion at
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heparin octasaccharide with 11 sulfates and no acetyl
groups (Figure 1b, FT-ICR spectra for other fractions
not shown). The theoretical value for the 6-charge state
is 370.3141, and the difference averaged over the three
charge states 5-, 6-, and 7- is 0.32 ppm. The measured
molecular mass of this isomer is 2227.9284 Da (theoret-
ical 2227.9285). The high-resolution of the FT-ICR
makes this accuracy possible.
CCL2 was incubated with the 11-sulfated octasaccha-
ride isomers and subsequently bound to a hydrophobic
column under low salt conditions. Samples of the load
(11-sulfated octasaccharide) and eluate (11-sulfated oc-
tasaccharide eluted by high salt) from the CCL2 enrich-
Figure 2. Variable disaccharide repeat of heparin and heparan
sulfate. The four possible disaccharide components of our 11-
sulfated octasaccharide are indicated, along with major MS1 ion
and MS2 diagnostic ion(s).
Figure 3. Structures of the four possible CCL-2
Arrows denote unsulfated positions.ment were extensively desalted, concentrated, and sub-
jected to complete enzymatic digestion to their
disaccharide constituents. These digested samples were
then quenched and analyzed on an LTQ mass spec-
trometer for disaccharide composition by comparison
of the diagnostic ions from the product ion spectra [29].
Standard mixes of known disaccharide composition
and concentration were also analyzed by LTQ-MS as
controls to monitor the identification and quantification
procedure. Using diagnostic ions (Figure 2) from spec-
tral data of the standard disaccharide mixes, response
factors for each of the four possible disaccharides were
calculated. Samples from the load and eluate fractions
that were digested were then processed using these
calculated response factors, and ratios of disaccharide
concentration were determined [6]. The measured dis-
accharide composition is summarized in Table 1.
ing enriched heparin octasaccharide sequences.
Table 1. The disaccharide composition of each octasaccharide
fraction as calculated by LTQ-MS analysis
Calculated abundance of heparin disaccharide composition
Disaccharide
% Abundance
Load Eluate
III-S 8.86  3.38 23.96  6.40
II-S 85.73  5.44 74.46  6.32
I-H 5.33  3.46 1.50  0.86
Each 11-sulfated octasaccharide contained three I-S fully sulfated dis-
accharides and one singly unsulfated III-S, II-S, or I-H disaccharide.
Reported in this table is the percent abundance of these singly unsul-
fated disaccharides in each octasaccharide fraction. Results reflect
triplicate experiments from affinity enrichment to MS-MS analysis;
error is standard deviation between analyses of three datasets.bind
1118 SWEENEY ET AL. J Am Soc Mass Spectrom 2006, 17, 1114–1119Our data indicate that the total percentage of disac-
charide III-S is increased by a statistically significant
amount by CCL2 affinity enrichment. This indicates
that one or more of the four possible octasaccharide
sulfation sequences containing a III-S disaccharide sub-
unit are enriched by CCL2 binding (Figure 3, Table 1). It
should be noted, however, that since our assay did not
include the 3-O sulfated disaccharides, the disulfated
version of this isomer is not excluded as a possible
binder.
There are two possibilities for why this enrichment
occurs. First, possibly an unsulfated 6-O position of III-S
is forming a specific contact with CCL2, resulting in
increased affinity between octasaccharide and chemo-
kine. The other possibility is that loss of a 2-O (II-S) or
N (I-H) sulfate will result in significantly weakened
binding affinity between octasaccharide and CCL2 by
disrupting an interaction with a 2-O or N sulfate group.
Using the current assay, these hypotheses cannot be
differentiated. An analysis comparing CCL2 binding to
chemically synthesized heparin octasaccharides con-
taining one III-S disaccharide in defined positions
would be one approach to answering this question.
The heparan sulfate-binding site for several other
chemokines has also been studied [14 –16]. The heparan
sulfate binding sites for these chemokines were all fairly
large, in the range of 12–24 saccharide units. This size is
consistent with GAG binding to more than one site on
the chemokine dimer. Evidence in each publication was
presented, which supports the model that two sulfated
regions exist on each GAG molecule, linked by a N
acetylated region of low sulfation. Not surprisingly, the
basic chemokines CXCL8 and CXCL4 bound with
greater affinity to more highly sulfated heparan sulfate,
but this was also found to be true for the acidic
chemokine CCL3. Some differences, other than the
length of the heparan sulfate, were observed in the
binding of these chemokines. CXCL8 showed little pref-
erence for N or O sulfate positioning, though at least one
I-S disaccharide appears to be important for the interac-
tion. CXCL4 bound 2-O sulfated regions preferably to 6-O
sulfated regions of GAG, and while it did not have an
absolute requirement of N sulfation to bind, high levels of
N sulfation appear in the binding site. CCL3, which had
the smallest GAG binding site of the three at 12–14
saccharides, had a binding site similar to CXCL4 but
showed an absolute requirement for at least some 6-O
sulfation to bind, whereas CXCL4 did not.
The heparin octasaccharides studied herein are sub-
stantially shorter and more sulfated than the commen-
surate heparan sulfate sequences that have been show
to bind CXCL8, CXCL4, and CCL3. They mimic only
one heparan sulfate S-domain and have no N-acetylated
linker region. However, the proposed models for hepa-
ran sulfate binding to these three chemokines all show
one molecule of heparan sulfate bridging two GAG
binding sites on the chemokines. The two binding site
model is in agreement with the spacing of the GAG
binding sites on the proposed dimer and tetramerstructures of some chemokines. CCL2, however, forms
a tetramer with one extended GAG binding site on each
side [30, 3]. Further, addition of heparin octasaccharide
has been shown to promote formation of the CCL2
tetramer. As the GAG binding site of CCL2 is highly
basic, any heparan sulfate chain that binds would have
to be highly sulfated, suggesting that our heparin
octasaccharide may not be very dissimilar to the actual
heparan sulfate ligand.
Conclusions
Our data supports the hypothesis that the chemokine
CCL2 preferentially binds highly sulfated heparin se-
quences, in particular those that contain at least one
III-S disaccharide. Further studies are currently under-
way to identify specific heparan sulfate binders and to
further probe the significance of positional isomers in
CCL2 binding.
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